NASDAQ:NTRPNeurotrope Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neurotrope Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.22 +0.01 (+0.83 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$1.18Now: $1.22▼$1.2650-Day Range$1.12MA: $1.18▼$1.3152-Week Range$0.63Now: $1.22▼$6.60Volume283,672 shsAverage Volume271,142 shsMarket Capitalization$28.88 millionP/E RatioN/ADividend YieldN/ABeta2.18 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingNeurotrope has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.00, Neurotrope has a potential downside of 18.0% from its current price of $1.22.Amount of Analyst CoverageNeurotrope has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesNeurotrope has received 180 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeurotrope has received 208 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeurotrope has received 53.61% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote “Outperform” if you believe NTRP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeurotrope does not currently pay a dividend.Dividend GrowthNeurotrope does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurotrope insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.70% of the stock of Neurotrope is held by insiders.Percentage Held by InstitutionsOnly 8.49% of the stock of Neurotrope is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioNeurotrope has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.79 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTRP Previous Symbol CUSIPN/A CIK1513856 Webwww.neurotropebioscience.com Phone973-242-0005Debt Debt-to-Equity RatioN/A Current Ratio93.66 Quick Ratio93.66Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book0.92Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-15,140,000.00 Net MarginsN/A Return on Equity-57.74% Return on Assets-56.20%Miscellaneous Employees6 Outstanding Shares23,670,000Market Cap$28.88 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable $1.22 +0.01 (+0.83 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NTRP News and Ratings via Email Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter. Neurotrope (NASDAQ:NTRP) Frequently Asked Questions How has Neurotrope's stock been impacted by COVID-19 (Coronavirus)? Neurotrope's stock was trading at $0.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NTRP stock has increased by 40.2% and is now trading at $1.22. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Neurotrope? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Neurotrope. When is Neurotrope's next earnings date? Neurotrope is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Neurotrope. How were Neurotrope's earnings last quarter? Neurotrope Inc (NASDAQ:NTRP) posted its earnings results on Friday, June, 12th. The company reported ($0.14) earnings per share (EPS) for the quarter. View Neurotrope's earnings history. What price target have analysts set for NTRP? 2 analysts have issued twelve-month price objectives for Neurotrope's shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Neurotrope's share price to reach $1.00 in the next year. This suggests that the stock has a possible downside of 18.0%. View analysts' price targets for Neurotrope. Has Neurotrope been receiving favorable news coverage? News headlines about NTRP stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Neurotrope earned a coverage optimism score of -3.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Neurotrope. Who are some of Neurotrope's key competitors? Some companies that are related to Neurotrope include Bellerophon Therapeutics (BLPH), Rockwell Medical (RMTI), Chembio Diagnostics (CEMI), Savara (SVRA), Sesen Bio (SESN), Otonomy (OTIC), Iterum Therapeutics (NRBO), Qualigen (QLGN), AcelRx Pharmaceuticals (ACRX), Adamas Pharmaceuticals (ADMS), Leap Therapeutics (LPTX), Zynerba Pharmaceuticals (ZYNE), Endonovo Therapeutics (ENDV), Evoke Pharma (EVOK) and Recro Pharma (REPH). View all competitors. What other stocks do shareholders of Neurotrope own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurotrope investors own include Sarepta Therapeutics (SRPT), Fibrocell Science (FCSC), Neos Therapeutics (NEOS), Alibaba Group (BABA), Canopy Growth (CGC), Pieris Pharmaceuticals (PIRS), Intel (INTC), Iovance Biotherapeutics (IOVA), Adamis Pharmaceuticals (ADMP) and American Equity Investment Life (AEL). Who are Neurotrope's key executives? Neurotrope's management team includes the following people: Dr. Charles S. Ryan, CEO & Director (Age 55)Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 77)Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 59)Dr. Michael Ciraolo, Gen. Counsel & COO (Age 46)Mr. Jeffrey Benison, Director of Corp. Communications What is Neurotrope's stock symbol? Neurotrope trades on the NASDAQ under the ticker symbol "NTRP." How do I buy shares of Neurotrope? Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Neurotrope's stock price today? One share of NTRP stock can currently be purchased for approximately $1.22. How big of a company is Neurotrope? Neurotrope has a market capitalization of $28.88 million. Neurotrope employs 6 workers across the globe. What is Neurotrope's official website? The official website for Neurotrope is www.neurotropebioscience.com. How can I contact Neurotrope? Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected] This page was last updated on 8/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
